Alternative rapamycin treatment regimens mitigate the impact of rapamycin on glucose homeostasis and the immune system

Inhibition of the mechanistic target of rapamycin (mTOR) signaling pathway by the FDA‐approved drug rapamycin has been shown to promote lifespan and delay age‐related diseases in model organisms including mice. Unfortunately, rapamycin has potentially serious side effects in humans, including glucos...

Πλήρης περιγραφή

Αποθηκεύτηκε σε:
Λεπτομέρειες βιβλιογραφικής εγγραφής
Τόπος έκδοσης:Aging Cell
Κύριοι συγγραφείς: Arriola Apelo, Sebastian I., Neuman, Joshua C., Baar, Emma L., Syed, Faizan A., Cummings, Nicole E., Brar, Harpreet K., Pumper, Cassidy P., Kimple, Michelle E., Lamming, Dudley W.
Μορφή: Artigo
Γλώσσα:Inglês
Έκδοση: John Wiley and Sons Inc. 2015
Θέματα:
Original Articles
Διαθέσιμο Online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4717280/
https://ncbi.nlm.nih.gov/pubmed/26463117
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/acel.12405
Ετικέτες: Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!

Παρόμοια τεκμήρια